ArticleIn vivo (Athens, Greece)
A miR-124-3p/PKC-δ Regulatory Axis Restrains Bladder Cancer Growth and Malignant Progression.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimBladder cancer is characterized by high rates of recurrence and metastasis, underscoring the need for novel molecular targets. Protein kinase C delta (PKC-δ) has been implicated in tumor progression, yet its regulatory mechanisms in bladder cancer remain unclear. MicroRNAs (miRNAs) function as crucial post-transcriptional regulators, and miR-124-3p is recognized as a potent tumor suppressor that inhibits oncogenic signaling across various malignancies. However, its specific interaction with PKC-δ in bladder cancer has not been established. This study aimed to investigate the regulatory role of the miR-124-3p/PKC-δ axis in modulating the malignant phenotypes of bladder cancer cells. MATERIALS AND
methodsHuman bladder cancer cell lines TSGH8301 and T24 were treated with the PKC inhibitor rottlerin or transfected with miR-124-3p mimic. Cell viability, proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and stemness were evaluated using cytotoxicity assays, Transwell assays, sphere formation assays, flow cytometry, and western blotting.
resultsRottlerin suppressed bladder cancer cell proliferation and upregulated miR-124-3p expression. Overexpression of miR-124-3p reduced PKC-δ expression and phosphorylation, inhibited migration, invasion, EMT, and stemness, and phenocopied the effects of PKC inhibition.
conclusionmiR-124-3p negatively regulates PKC-δ signaling in bladder cancer cells, forming a novel miR-124-3p/PKC-δ axis that suppresses bladder cancer progression and may offer therapeutic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.